nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—polycystic ovary syndrome	0.71	1	CbGaD
Metoclopramide—CYP17A1—ovarian follicle—polycystic ovary syndrome	0.0208	0.305	CbGeAlD
Metoclopramide—HTR4—adrenal cortex—polycystic ovary syndrome	0.00669	0.0982	CbGeAlD
Metoclopramide—HTR4—pituitary gland—polycystic ovary syndrome	0.00541	0.0793	CbGeAlD
Metoclopramide—HTR4—adrenal gland—polycystic ovary syndrome	0.00483	0.0709	CbGeAlD
Metoclopramide—CYP11B2—adrenal cortex—polycystic ovary syndrome	0.00377	0.0553	CbGeAlD
Metoclopramide—CYP11B1—adrenal cortex—polycystic ovary syndrome	0.00377	0.0553	CbGeAlD
Metoclopramide—Sunitinib—INSR—polycystic ovary syndrome	0.00275	0.551	CrCbGaD
Metoclopramide—CYP11B2—adrenal gland—polycystic ovary syndrome	0.00272	0.0399	CbGeAlD
Metoclopramide—CYP11B1—adrenal gland—polycystic ovary syndrome	0.00272	0.0399	CbGeAlD
Metoclopramide—CYP2D6—urine—polycystic ovary syndrome	0.00251	0.0368	CbGeAlD
Metoclopramide—CYP11B2—endocrine gland—polycystic ovary syndrome	0.00236	0.0346	CbGeAlD
Metoclopramide—CYP11B1—endocrine gland—polycystic ovary syndrome	0.00236	0.0346	CbGeAlD
Metoclopramide—CYP17A1—adrenal cortex—polycystic ovary syndrome	0.0023	0.0338	CbGeAlD
Metoclopramide—Sunitinib—FLT4—polycystic ovary syndrome	0.00224	0.449	CrCbGaD
Metoclopramide—CYP17A1—adrenal gland—polycystic ovary syndrome	0.00166	0.0244	CbGeAlD
Metoclopramide—CYP17A1—female gonad—polycystic ovary syndrome	0.00155	0.0227	CbGeAlD
Metoclopramide—CYP17A1—endocrine gland—polycystic ovary syndrome	0.00144	0.0211	CbGeAlD
Metoclopramide—Function kidney decreased—Metformin—polycystic ovary syndrome	0.000989	0.325	CcSEcCtD
Metoclopramide—DRD2—pituitary gland—polycystic ovary syndrome	0.000893	0.0131	CbGeAlD
Metoclopramide—CHRM1—endocrine gland—polycystic ovary syndrome	0.000859	0.0126	CbGeAlD
Metoclopramide—DRD2—endocrine gland—polycystic ovary syndrome	0.000692	0.0101	CbGeAlD
Metoclopramide—CYP2D6—female gonad—polycystic ovary syndrome	0.000447	0.00656	CbGeAlD
Metoclopramide—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000416	0.0061	CbGeAlD
Metoclopramide—Blood disorder—Metformin—polycystic ovary syndrome	0.000258	0.085	CcSEcCtD
Metoclopramide—Renal impairment—Metformin—polycystic ovary syndrome	0.000165	0.0541	CcSEcCtD
Metoclopramide—Neutropenia—Metformin—polycystic ovary syndrome	0.000127	0.0416	CcSEcCtD
Metoclopramide—Drowsiness—Metformin—polycystic ovary syndrome	0.000121	0.0397	CcSEcCtD
Metoclopramide—Bradycardia—Metformin—polycystic ovary syndrome	0.00011	0.0363	CcSEcCtD
Metoclopramide—Flushing—Metformin—polycystic ovary syndrome	0.000101	0.0331	CcSEcCtD
Metoclopramide—Muscle spasms—Metformin—polycystic ovary syndrome	9.07e-05	0.0298	CcSEcCtD
Metoclopramide—Tremor—Metformin—polycystic ovary syndrome	8.84e-05	0.0291	CcSEcCtD
Metoclopramide—Palpitations—Metformin—polycystic ovary syndrome	8.34e-05	0.0274	CcSEcCtD
Metoclopramide—Hypertension—Metformin—polycystic ovary syndrome	8.15e-05	0.0268	CcSEcCtD
Metoclopramide—Oedema—Metformin—polycystic ovary syndrome	7.7e-05	0.0253	CcSEcCtD
Metoclopramide—Hypotension—Metformin—polycystic ovary syndrome	7.2e-05	0.0237	CcSEcCtD
Metoclopramide—Dyspnoea—Metformin—polycystic ovary syndrome	6.87e-05	0.0226	CcSEcCtD
Metoclopramide—Somnolence—Metformin—polycystic ovary syndrome	6.85e-05	0.0225	CcSEcCtD
Metoclopramide—Fatigue—Metformin—polycystic ovary syndrome	6.64e-05	0.0218	CcSEcCtD
Metoclopramide—Feeling abnormal—Metformin—polycystic ovary syndrome	6.35e-05	0.0209	CcSEcCtD
Metoclopramide—Urticaria—Metformin—polycystic ovary syndrome	6.12e-05	0.0201	CcSEcCtD
Metoclopramide—Asthenia—Metformin—polycystic ovary syndrome	5.53e-05	0.0182	CcSEcCtD
Metoclopramide—Diarrhoea—Metformin—polycystic ovary syndrome	5.27e-05	0.0173	CcSEcCtD
Metoclopramide—Dizziness—Metformin—polycystic ovary syndrome	5.09e-05	0.0167	CcSEcCtD
Metoclopramide—Rash—Metformin—polycystic ovary syndrome	4.86e-05	0.016	CcSEcCtD
Metoclopramide—Dermatitis—Metformin—polycystic ovary syndrome	4.85e-05	0.016	CcSEcCtD
Metoclopramide—Headache—Metformin—polycystic ovary syndrome	4.83e-05	0.0159	CcSEcCtD
Metoclopramide—Nausea—Metformin—polycystic ovary syndrome	4.57e-05	0.015	CcSEcCtD
Metoclopramide—CHRM1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	2.47e-05	0.000115	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SLC2A4—polycystic ovary syndrome	2.47e-05	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—LHB—polycystic ovary syndrome	2.45e-05	0.000115	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	2.45e-05	0.000115	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PDE3B—polycystic ovary syndrome	2.44e-05	0.000114	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	2.43e-05	0.000114	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—GNAS—polycystic ovary syndrome	2.42e-05	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	2.41e-05	0.000113	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GNAS—polycystic ovary syndrome	2.4e-05	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	2.4e-05	0.000112	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—GHRL—polycystic ovary syndrome	2.38e-05	0.000111	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TH—polycystic ovary syndrome	2.37e-05	0.000111	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—SCT—polycystic ovary syndrome	2.35e-05	0.00011	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTGER3—polycystic ovary syndrome	2.33e-05	0.000109	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LHCGR—polycystic ovary syndrome	2.33e-05	0.000109	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP19A1—polycystic ovary syndrome	2.32e-05	0.000108	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SLC2A4—polycystic ovary syndrome	2.31e-05	0.000108	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—SCT—polycystic ovary syndrome	2.3e-05	0.000108	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—NCOR1—polycystic ovary syndrome	2.29e-05	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTGER3—polycystic ovary syndrome	2.28e-05	0.000106	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LHCGR—polycystic ovary syndrome	2.28e-05	0.000106	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	2.24e-05	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FSHR—polycystic ovary syndrome	2.22e-05	0.000104	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	2.22e-05	0.000104	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	2.22e-05	0.000104	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	2.19e-05	0.000103	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	2.19e-05	0.000102	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—POMC—polycystic ovary syndrome	2.18e-05	0.000102	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTAFR—polycystic ovary syndrome	2.18e-05	0.000102	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CYP1A1—polycystic ovary syndrome	2.17e-05	0.000101	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP19A1—polycystic ovary syndrome	2.17e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GHRL—polycystic ovary syndrome	2.16e-05	0.000101	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IRS2—polycystic ovary syndrome	2.15e-05	0.000101	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	2.14e-05	0.0001	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTAFR—polycystic ovary syndrome	2.13e-05	9.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	2.11e-05	9.88e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—LEP—polycystic ovary syndrome	2.1e-05	9.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RACGAP1—polycystic ovary syndrome	2.09e-05	9.78e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GNAS—polycystic ovary syndrome	2.07e-05	9.68e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	2.07e-05	9.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	2.07e-05	9.67e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	2.06e-05	9.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	2.05e-05	9.61e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.03e-05	9.52e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—MTHFR—polycystic ovary syndrome	2.02e-05	9.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	2.01e-05	9.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INHBB—polycystic ovary syndrome	2e-05	9.36e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FST—polycystic ovary syndrome	1.98e-05	9.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.97e-05	9.22e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NCOR1—polycystic ovary syndrome	1.97e-05	9.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INHBB—polycystic ovary syndrome	1.96e-05	9.17e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.96e-05	9.16e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GNAS—polycystic ovary syndrome	1.94e-05	9.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LHB—polycystic ovary syndrome	1.94e-05	9.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.89e-05	8.85e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IRS1—polycystic ovary syndrome	1.88e-05	8.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PDE3B—polycystic ovary syndrome	1.87e-05	8.74e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP1A1—polycystic ovary syndrome	1.87e-05	8.74e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NCOR1—polycystic ovary syndrome	1.84e-05	8.63e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.83e-05	8.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PDE3B—polycystic ovary syndrome	1.83e-05	8.56e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.83e-05	8.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	1.82e-05	8.53e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SCT—polycystic ovary syndrome	1.81e-05	8.48e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—POMC—polycystic ovary syndrome	1.81e-05	8.46e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—INS—polycystic ovary syndrome	1.8e-05	8.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.79e-05	8.37e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	1.78e-05	8.34e-05	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—IL6—polycystic ovary syndrome	1.77e-05	8.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	1.76e-05	8.22e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	1.76e-05	8.22e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP1A1—polycystic ovary syndrome	1.75e-05	8.18e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—MTHFR—polycystic ovary syndrome	1.74e-05	8.15e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1—polycystic ovary syndrome	1.74e-05	8.14e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT2—polycystic ovary syndrome	1.74e-05	8.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.73e-05	8.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FSHR—polycystic ovary syndrome	1.7e-05	7.96e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGF18—polycystic ovary syndrome	1.7e-05	7.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RBP4—polycystic ovary syndrome	1.69e-05	7.89e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—POMC—polycystic ovary syndrome	1.67e-05	7.8e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FSHR—polycystic ovary syndrome	1.67e-05	7.79e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.66e-05	7.77e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.65e-05	7.74e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.65e-05	7.73e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PPARG—polycystic ovary syndrome	1.64e-05	7.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—POMC—polycystic ovary syndrome	1.63e-05	7.63e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MTHFR—polycystic ovary syndrome	1.63e-05	7.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.62e-05	7.58e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—POMC—polycystic ovary syndrome	1.62e-05	7.56e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—INS—polycystic ovary syndrome	1.61e-05	7.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.6e-05	7.49e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—YAP1—polycystic ovary syndrome	1.57e-05	7.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.57e-05	7.33e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.56e-05	7.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GAB1—polycystic ovary syndrome	1.55e-05	7.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.52e-05	7.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FST—polycystic ovary syndrome	1.52e-05	7.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.51e-05	7.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.5e-05	7.01e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FST—polycystic ovary syndrome	1.48e-05	6.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INSR—polycystic ovary syndrome	1.48e-05	6.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LHB—polycystic ovary syndrome	1.48e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.48e-05	6.91e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	1.47e-05	6.89e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.47e-05	6.86e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LHB—polycystic ovary syndrome	1.45e-05	6.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.45e-05	6.77e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.42e-05	6.63e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PPARG—polycystic ovary syndrome	1.41e-05	6.61e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.41e-05	6.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.4e-05	6.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.4e-05	6.54e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	1.4e-05	6.53e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—POMC—polycystic ovary syndrome	1.39e-05	6.52e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.39e-05	6.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SCT—polycystic ovary syndrome	1.39e-05	6.49e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—INS—polycystic ovary syndrome	1.39e-05	6.48e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PGR—polycystic ovary syndrome	1.37e-05	6.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.37e-05	6.42e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.37e-05	6.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.37e-05	6.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SCT—polycystic ovary syndrome	1.36e-05	6.35e-05	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—polycystic ovary syndrome	1.36e-05	6.34e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.34e-05	6.27e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	1.33e-05	6.23e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—polycystic ovary syndrome	1.33e-05	6.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—polycystic ovary syndrome	1.33e-05	6.21e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.32e-05	6.19e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—polycystic ovary syndrome	1.32e-05	6.18e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POMC—polycystic ovary syndrome	1.3e-05	6.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGF18—polycystic ovary syndrome	1.3e-05	6.09e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—INS—polycystic ovary syndrome	1.3e-05	6.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.3e-05	6.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RBP4—polycystic ovary syndrome	1.29e-05	6.03e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PLAT—polycystic ovary syndrome	1.28e-05	5.98e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GHRL—polycystic ovary syndrome	1.28e-05	5.98e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGF18—polycystic ovary syndrome	1.27e-05	5.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.27e-05	5.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RBP4—polycystic ovary syndrome	1.26e-05	5.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	1.26e-05	5.88e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.24e-05	5.82e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.23e-05	5.76e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ATF1—polycystic ovary syndrome	1.22e-05	5.7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—YAP1—polycystic ovary syndrome	1.2e-05	5.63e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.19e-05	5.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GAB1—polycystic ovary syndrome	1.19e-05	5.56e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.19e-05	5.55e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.18e-05	5.53e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—YAP1—polycystic ovary syndrome	1.18e-05	5.51e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GAB1—polycystic ovary syndrome	1.16e-05	5.44e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.14e-05	5.31e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INSR—polycystic ovary syndrome	1.14e-05	5.31e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.13e-05	5.3e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NGFR—polycystic ovary syndrome	1.12e-05	5.26e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—POMC—polycystic ovary syndrome	1.12e-05	5.23e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRL—polycystic ovary syndrome	1.11e-05	5.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INSR—polycystic ovary syndrome	1.11e-05	5.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.08e-05	5.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.07e-05	5.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.06e-05	4.97e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.06e-05	4.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.06e-05	4.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PGR—polycystic ovary syndrome	1.05e-05	4.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.04e-05	4.86e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.03e-05	4.83e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PGR—polycystic ovary syndrome	1.03e-05	4.81e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.01e-05	4.72e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GNAS—polycystic ovary syndrome	9.81e-06	4.59e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	9.78e-06	4.57e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	9.78e-06	4.57e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	9.78e-06	4.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLAT—polycystic ovary syndrome	9.57e-06	4.48e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GHRL—polycystic ovary syndrome	9.57e-06	4.48e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.42e-06	4.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.34e-06	4.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	9.33e-06	4.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.22e-06	4.31e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRG1—polycystic ovary syndrome	9.17e-06	4.29e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ATF1—polycystic ovary syndrome	9.13e-06	4.27e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.09e-06	4.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.05e-06	4.24e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	9e-06	4.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.9e-06	4.16e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.86e-06	4.14e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	8.72e-06	4.08e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	8.61e-06	4.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	8.55e-06	4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	8.53e-06	3.99e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NGFR—polycystic ovary syndrome	8.42e-06	3.94e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	8.4e-06	3.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—polycystic ovary syndrome	8.37e-06	3.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRL—polycystic ovary syndrome	8.35e-06	3.91e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.22e-06	3.85e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.09e-06	3.79e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	8.07e-06	3.78e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.05e-06	3.76e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	7.97e-06	3.73e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.92e-06	3.71e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—polycystic ovary syndrome	7.86e-06	3.68e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS2—polycystic ovary syndrome	7.85e-06	3.67e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	7.69e-06	3.6e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	7.53e-06	3.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	7.5e-06	3.51e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	7.41e-06	3.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GNAS—polycystic ovary syndrome	7.34e-06	3.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.15e-06	3.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	7.02e-06	3.28e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	7e-06	3.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	6.87e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	6.86e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	6.6e-06	3.09e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	6.57e-06	3.07e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TH—polycystic ovary syndrome	6.41e-06	3e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	6.35e-06	2.97e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	6.35e-06	2.97e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	6.24e-06	2.92e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.03e-06	2.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	6.01e-06	2.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	5.88e-06	2.75e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	5.88e-06	2.75e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	5.86e-06	2.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	5.76e-06	2.69e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	5.25e-06	2.45e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	5.23e-06	2.45e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.13e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	5.05e-06	2.36e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	5.02e-06	2.35e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	4.99e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	4.94e-06	2.31e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	4.92e-06	2.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	4.86e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	4.86e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	4.86e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.76e-06	2.23e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.75e-06	2.22e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	4.73e-06	2.21e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.61e-06	2.16e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.52e-06	2.11e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	4.41e-06	2.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.15e-06	1.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	3.72e-06	1.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.64e-06	1.7e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	3.57e-06	1.67e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	3.52e-06	1.65e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—INS—polycystic ovary syndrome	3.5e-06	1.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.17e-06	1.48e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.11e-06	1.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	2.87e-06	1.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	2.2e-06	1.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	2.15e-06	1.01e-05	CbGpPWpGaD
